n°86

December 2006

Issue Contents
Editorial

Free  Common property

p.202
Prescrire depends on readers' subsciptions only

Marketing Authorisations

Inhaled human insulin (type 1 and type 2 diabetes) (new drug)

p.203-209
No short-term advantages, too many unknowns in the long term

Varenicline (smoking cessation) (new drug)

p.210-212
No better than nicotine

Nicotinic acid (hypercholesterolaemia) (new/old drug)

p.213-216
Immediate or sustained release: too risky for a drug with no proven benefit

Tipranavir (HIV protease inhibitor) (new drug)

p.217-219
A last resort

Risperidone and mania: unethical trials

p.219
No advantage for patients

Rasagiline (Parkinson's disease)

p.220
A simple me-too

Alluring trial acronyms

p.220
Naming clinical trials is part of marketing strategies

Terlipressin (type I hepatorenal syndrome)

p.220
An extra window of time before liver transplantation

Sildenafil (pulmonary arterial hypertension)

p.221
No better than bosentan

Fluoxetine (bulimia nervosa)

p.221
Don't use

Adverse Effects

SSRI antidepressants and birth defects (p. 222)

p.222-223
Troubling cases, especially with paroxetine

ACE inhibitors and birth defects

p.223
ACE inhibitors should be avoided during pregnancy

Neuroleptics: increased rate of venous thromboembolic events

p.224
Caution before prescribing a neuroleptic, also during treatment

Clarithromycin in coronary heart disease: excess mortality in the long term (p. 225)

p.225
Troubling results in one trial

Domperidone and sudden death

p.226
A serious risk against poorly established efficacy

Promethazine and sudden infant death

p.226
Beware family cabinet

Reviews

Infant immunisation with a pneumococcal conjugate vaccine

p.227-233
From the age of 2 months, for all infants

Prescrire's proposals

p.231
Infant immunisation with pneumococcal conjugate vaccine

Iron supplementation

p.233
Unexpected results of a clinical trial

Melatonin and sleep disorders

p.233
No better than placebo

Outlook

Free  WTO agreement on medicines: a false solution

p.234-235
Hyped up announcements but still no medicines

Free  Online postings of the opinions of the French Transparency Committee: incomplete and difficult to access

p.235-236
Much room for improvement

Forum

Free  Postmenopausal hormone replacement therapy: what is the risk of breast cancer?

p.237-238
Long term therapy should be avoided

Free  Clopidogrel and mortality

p.238-239
Prescrire' assessment challenged and confirmed

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe